This dog meat stock is setting up for a short squeeze

Plus today’s other big movers                                                                                                                                                                                                                                                                                                                                                                                                                 *Together with Genprex (Nasdaq: GNPX) Hi 360! As always, here are our top investing ideas today – these setups look primed! And a heads up that Jeff Bishop will be offering free training TODAY in at 1pm EST – he’s just hit 90 Rocket Trades (at the time of writing this) since starting this challenge in Bullseye Unlimited a few months ago 🤯 Come here what his big plans are to close this out and begin a new 100🚀Challenge → [use this link at 1pm EST](. MNPR - Up over 18% in pre-market after encouraging Phase 1b trial update HOTH - Up over 20% after EF Hutton gives a Buy rating CHWY - Up over 17% after beating earnings estimates *A Message From Market News Reporting 📈 Technical Trade Alert 📈 Genprex (Nasdaq: GNPX) Today, we have an incredible opportunity for you to look at as you start your day. Jeff Bishop’s “Gamma Trigger” indicators have flagged an emerging move happening with a small biotech stock right now. GNPX has been rolling out some incredible press releases recently, and it appears the market is starting to take notice. Jason Kolbert, Director of Research at Dawson James certainly has taken notice. He slapped a price target on GNPX that is over 240% higher than current price levels. Spend some time looking into GNPX right now, and see what the market is buzzing about. Get started by looking at the [great information our friends at Market News Report have put together]( on GNPX today. Of course, always do your own research and make sure you are comfortable with the risks when it comes to any stock you decide to trade. No matter what… make sure you are keeping a close eye on GNPX today! 👀 *Sponsored content by Lifewater Media, please see disclosures below MNPR - Up over 18% in pre-market after encouraging Phase 1b trial update Monopar Therapeutics (MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer, today announced an encouraging Phase 1b update of its drug camsirubicin in patients with advanced soft tissue sarcoma (ASTS). Camsirubicin has been designed to retain the anti-cancer activity while avoiding the irreversible heart damage that is seen with doxorubicin. Doxorubicin is one of the most widely used cancer drugs worldwide with FDA approval in ASTS and 13 additional cancer indications. Update: - One patient at the 520 mg/m2 dose level, unresectable at study entry, was deemed eligible for tumor resection after several cycles of camsirubicin treatment and a corresponding 21% reduction in tumor dimensions. This patient recently underwent surgical resection of the cancer. - 100% of patients (3 of 3) at the fourth dose-level (520mg/m2 ) achieved stable disease, and had either a net reduction or no overall change in tumor size per RECIST 1.1 while on study drug. This is promising news for the nano cap and the stock is trading up 18% as a result. The $1.10 level has been support so far in the pre-market and will be an important area to watch. Above it, targets to the upside are $1.22 and then the pre-market high at $1.34. Beyond that, targets are $1.45. $1.60, $1.75, $2, $2.40 and then a gap to fill at $2.98. Below $1.10, there is potential support at $1 and a gap to fill at $0.9780. HOTH - Up over 20% after EF Hutton gives a Buy rating Hoth Therapeutics (HOTH) is a clinical-stage biopharmaceutical company, focusing on developing therapies for unmet medical needs. EF Hutton assumed a Buy rating on the stock yesterday in the after hours with a $14 price target and the stock is trading 20% higher this morning as a result. The price target indicates more than 600% upside from current levels. The $1.88 area has acted as support in the after-hours and pre-market and will be an important level to watch. Above it, targets to the upside are $2, with the pre-market high of $2.23 above that. Beyond that important potential resistance, targets are $2.40, $2.47, $2.63 with $3 and $3.60 above that. Below $1.88, there is potential support at $1.80 and a gap to fill at $1.59. CHWY - Up over 17% after beating earnings estimates Chewy, Inc (CHWY) engages in the pure play e-commerce business in the United States. It provides pet food and treats, pet supplies and pet medications, and other pet-health products, as well as pet services. CHWY reported Q1 EPS of $0.05 vs the -$0.04 estimate. Revenue for the quarter came in at $2.78 billion vs the $2.73 billion estimate. Investors cheered the company’s positive earnings as analysts expected negative earnings. CHWY has a short float of over 22% and the positive earnings could have some shorts in trouble this morning. The $34 area was resistance in the after-hours and now becomes a potential support level in the pre-market. Above it, targets to the upside are $35 and then the pre-market high of $35.38. Beyond that level, $36, $38 and then $40 come into play. Below $34, there is potential support at $33.40, $32.55, $32, $31, $30.50, $30 and then a gap to fill at $29.49. [Economic Calendar]( To Your Success! Please see disclosures below.   Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull  *PAID ADVERTISEMENT. RagingBull has been paid ten thousand dollars by ach bank transfer by Lifewater Media for advertising Genprex Inc. from a period beginning on June 1, 2023 through June 2 of the same year. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Raging Bull, do not hold a position in Genprex Inc. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Genprex Inc., increased trading volume, and possibly an increased share price of the Genprex Inc. securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www. sec. gov/ edgar/ searchedgar/ companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. WE MAY HOLD SECURITIES DISCUSSED. Raging bull. com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. [tw]( Update your email preferences or unsubscribe [here]( © 360wallstreet 62 Calef Hwy. #233 Lee, NH 03861, United States [[beehiiv logo]Powered by beehiiv](